期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases 被引量:7
1
作者 Thekkuttuparambil Ananthanarayanan Ajith thankamani gopinathan jayakumar 《World Journal of Cardiology》 CAS 2014年第10期1091-1099,共9页
Mitochondria are one of the major sites for the genera-tion of reactive oxygen species(ROS) as an undesirable side product of oxidative energy metabolism. Damaged mitochondria can augment the generation of ROS. Dys-fu... Mitochondria are one of the major sites for the genera-tion of reactive oxygen species(ROS) as an undesirable side product of oxidative energy metabolism. Damaged mitochondria can augment the generation of ROS. Dys-function of mitochondria increase the risk for a large number of human diseases, including cardiovascular diseases(CVDs). Heart failure(HF) following ischemic heart disease, infantile cardiomyopathy and cardiac hypertrophy associated with left ventricular dilations are some of the CVDs in which the role of mitochon-drial oxidative stress has been reported. Advances in mitochondrial research during the last decade focused on the preservation of its function in the myocardium, which is vital for the cellular energy production. Expe-rimental and clinical trials have been conducted using mitochondria-targeted molecules like: MnSOD mimetics, such as EUK-8, EUK-134 and MitoSOD; choline esters of glutathione and N-acetyl-L-cysteine; triphenylphospho-nium ligated vitamin E, lipoic acid, plastoquinone andmitoCoQ10; and Szeto-Schiller(SS)- peptides(SS-02 and SS-31). Although many results are inconclusive, some of the findings, especially on CoQ10, are worthwhile. This review summarizes the role of mitochondria-tar-geted delivery of agents and their consequences in the control of HF. 展开更多
关键词 CARDIOVASCULAR diseases OXIDATIVE stress ANTIOXIDANT Electron transport chain MITOCHONDRIAL medicine Heart failure
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部